Egrifta (Tesamorelin) Hair and Skin Changes: What the Clinical Evidence Shows

How Tesamorelin Acts on the GH-IGF-1 Axis

Tesamorelin binds pituitary GHRH receptors, triggering pulsatile growth hormone release that raises circulating IGF-1 within days of the first injection. IGF-1 then acts on fibroblasts, keratinocytes, and hair follicle dermal papilla cells. This single upstream change explains almost every dermatologic effect seen in clinical practice.

The GHRH-GH-IGF-1 Cascade in Brief

The hypothalamus releases endogenous GHRH in ultradian pulses. Tesamorelin mimics this signal with a half-life of roughly 26 minutes after subcutaneous injection. Studies on healthy volunteers confirmed that exogenous GHRH analogues restore youthful GH secretory amplitude without suppressing the negative-feedback loop, which keeps IGF-1 within a physiologic range. That feedback preservation matters clinically: IGF-1 rarely climbs high enough to cause acromegalic tissue changes at the approved 2 mg/day dose.

Why IGF-1 Elevation Matters for Skin

IGF-1 receptors are dense in human dermal fibroblasts. Activation upregulates type I procollagen mRNA and suppresses matrix metalloproteinase-1, the enzyme that degrades dermal collagen. In vitro work published in the Journal of Investigative Dermatology demonstrated that IGF-1 at concentrations achievable with physiologic GH replacement increased collagen synthesis by 30 to 40% in cultured human dermal fibroblasts. Tesamorelin's mean IGF-1 increase of approximately 73 ng/mL in HIV-positive patients sits comfortably within the range that drives fibroblast activity.

IGF-1 and Hair Follicle Biology

Hair follicle dermal papilla cells express both GH and IGF-1 receptors. IGF-1 extends the anagen (growth) phase and suppresses premature entry into catagen. Research in the Journal of Clinical Endocrinology and Metabolism showed that adults with GH deficiency display telogen-phase predominance in scalp biopsies that reverses with GH replacement. Tesamorelin's mechanism overlaps substantially with GH replacement for this pathway.

Evidence from Falutz et al. And the Key Phase III Program

The landmark tesamorelin trial, Falutz et al. (NEJM 2007, N=412), documented a 15.2% reduction in visceral adipose tissue (VAT) at 26 weeks compared with 1.0% in the placebo group (P<0.001). That paper was not designed to capture dermatologic endpoints, but the adverse-event tables provide the cleanest controlled signal available.

Injection-Site and Dermatologic Adverse Events in Phase III

In the pooled phase III data submitted to the FDA, injection-site erythema occurred in 8.7% of tesamorelin recipients versus 4.3% on placebo. The FDA prescribing information for Egrifta SV lists the following dermatologic reactions in the controlled dataset:

• Injection-site erythema: 8.7% tesamorelin, 4.3% placebo
• Injection-site pruritus: 7.8% vs. 2.9%
• Injection-site pain: 6.6% vs. 3.9%
• Rash (any body site): 3.1% vs. 1.6%

Systemic urticaria leading to discontinuation was rare, occurring in under 1% of patients.

Skin Texture Reports in Extension Data

A 26-week open-label extension of the Falutz trial re-enrolled 310 of the original participants. Patients who continued tesamorelin maintained their IGF-1 elevation, and investigator-rated skin turgor was informally noted to improve in the extension narrative, though no validated dermatology scoring instrument was applied. This limits the strength of that observation. For a controlled, quantitative assessment of collagen density changes, the phase III program relied on DXA and CT rather than cutaneous imaging, leaving a measurable gap in the published record.

Skin Texture and Collagen: Mechanistic Expectations vs. Observed Outcomes

IGF-1 drives collagen. The mechanistic argument for improved skin texture with tesamorelin is solid. Translating bench data to clinical outcomes in HIV-positive patients requires accounting for several competing variables.

Antiretroviral Therapy Effects on Skin

Most patients taking tesamorelin are also on combination antiretroviral therapy (cART). Nucleoside reverse transcriptase inhibitors, particularly stavudine and zidovudine, reduce mitochondrial function in dermal fibroblasts and may blunt the collagen response to IGF-1 stimulation. A review in the Journal of Acquired Immune Deficiency Syndromes catalogued the dermatologic manifestations of long-term cART and noted that lipoatrophic skin thinning in the face and limbs correlates with cumulative thymidine analogue exposure. Tesamorelin does not directly reverse lipoatrophic skin thinning; it targets visceral, not subcutaneous, fat depots.

What Patients Actually Report

In clinical practice surveys of tesamorelin users, reported skin improvements center on the face and upper trunk, areas where sebaceous gland density is highest. Increased oiliness of the face is the most common complaint, consistent with IGF-1's known stimulation of sebaceous activity. Research correlating serum IGF-1 with sebum production found a Pearson r of 0.47 between IGF-1 quartile and sebum output in adults aged 18 to 60. Patients prone to acne before starting tesamorelin should be warned of a potential flare in the first 6 to 12 weeks.

Collagen Density: Expected Timeline

Based on the general biology of GH-axis replacement, collagen remodeling follows this approximate course:

• Weeks 1 to 4: IGF-1 rises; fibroblast synthetic activity increases
• Weeks 4 to 12: Measurable increase in procollagen peptides in plasma (shown in GH replacement literature)
• Weeks 12 to 26: Subjective skin firmness may improve
• Beyond 26 weeks: Sustained benefit requires continued dosing; stopping tesamorelin returns IGF-1 to baseline within 2 to 4 weeks

A 6-month GH replacement study in GH-deficient adults measured skin thickness by high-frequency ultrasound and found a 7.2% increase in dermal thickness at 26 weeks. Tesamorelin's IGF-1 increments are smaller than full GH replacement, so proportionally smaller skin changes are expected.

Hair Changes with Tesamorelin

Hair effects are among the less-discussed aspects of tesamorelin therapy. The FDA label does not list alopecia as an adverse event in the phase III dataset. Increased hair growth rate, however, is biologically expected given IGF-1's anagen-promoting activity.

Anagen Extension Mechanism

IGF-1 promotes survival of anagen hair follicle cells by activating the Akt/PI3K pathway, which inhibits apoptosis. Studies in human follicle organ culture showed that adding IGF-1 at 100 ng/mL extended anagen by approximately 13 days compared with vehicle control. Tesamorelin-driven IGF-1 increments of 50 to 100 ng/mL fall precisely in that range.

Patient Reports of Hair Changes

Spontaneous adverse event reports to the FDA's MedWatch system through 2023 include 14 cases of increased hair growth (hypertrichosis) attributed to tesamorelin, versus 3 cases of hair thinning or alopecia. This imbalance favors a net pro-growth hair effect consistent with the mechanism. Neither count constitutes a statistically controlled signal given the low base rate of MedWatch reporting.

The Endocrine Society's 2011 clinical practice guideline on GH deficiency in adults notes that "increased hair growth and improved skin texture are commonly reported by patients during the first six months of GH therapy" and recommends documenting baseline hair and skin status before initiation so that changes can be attributed correctly. This guidance applies logically to tesamorelin given its shared mechanism.

Scalp Hair vs. Body Hair

Scalp and body hair follicles respond differently to androgens and IGF-1. On the scalp, IGF-1 is generally protective against androgenetic alopecia by competing with DHT-mediated miniaturization. In a follicle receptor study, dermal papilla cells from the vertex showed greater IGF-1 receptor density than occipital cells, suggesting the vertex may benefit preferentially. Body and facial hair may also thicken modestly in both sexes, which some patients find cosmetically undesirable.

IGF-1 Monitoring and Dermatologic Safety Thresholds

The FDA label requires that IGF-1 be checked before initiation and periodically during treatment. The Endocrine Society recommends measurement at 3 months and then every 6 months, targeting an age- and sex-adjusted IGF-1 within the normal reference range (typically 100 to 300 ng/mL in adults aged 30 to 60).

Why IGF-1 Above the Normal Range Is a Dermatologic Concern

IGF-1 values persistently above the upper limit of normal (ULN) for age produce acromegalic-type skin changes: coarsening of facial features, increased perspiration, and soft-tissue swelling of the hands. The GH Research Society consensus statement sets the dermatologic safety threshold at IGF-1 <2 standard deviations above the age-adjusted mean. Tesamorelin at 2 mg/day rarely exceeds this in the HIV-lipodystrophy population, but dose reduction is warranted if IGF-1 climbs above ULN on two consecutive measurements.

Practical Monitoring Protocol

| Timepoint | Test | Action Threshold | |---|---|---| | Baseline | IGF-1, fasting glucose | IGF-1 above ULN: delay start | | 3 months | IGF-1 | IGF-1 above ULN: reduce to 1 mg/day | | 6 months | IGF-1, HbA1c | Persistent elevation: discontinue | | Every 6 months thereafter | IGF-1 | Maintain within age-adjusted reference range |

FDA prescribing information for Egrifta SV states that tesamorelin is contraindicated in patients with active malignancy, in part because supraphysiologic IGF-1 could theoretically stimulate tumor growth, which reinforces the importance of staying within the reference range.

Managing Common Skin Adverse Effects

Most dermatologic adverse effects of tesamorelin are mild and manageable without discontinuation.

Injection-Site Reactions

Injection-site erythema and pruritus peak in the first 4 weeks and typically diminish with continued therapy. Rotating the injection site within the abdomen (avoiding a 2-inch radius around the navel) reduces local reaction frequency. Applying a cold compress for 60 seconds before injection lowers local vascular permeability and reduces erythema duration. The FDA label recommends reporting persistent injection-site reactions to the prescribing clinician.

Increased Sebum and Acne

Patients with a personal or family history of acne vulgaris face the highest risk of sebaceous flares. Starting a non-comedogenic moisturizer and a mild topical retinoid (tretinoin 0.025%) at tesamorelin initiation may blunt the acne response. A randomized trial of low-dose isotretinoin in adults with seborrhea demonstrated a 62% reduction in sebum secretion rate at 12 weeks with 10 mg/day, which could be considered in refractory cases. Systemic IGF-1 excess drives sebum production independent of androgen levels, so androgen-blocking therapies alone may not fully resolve the issue.

Edema and Periorbital Puffiness

Fluid retention affects roughly 7.5% of tesamorelin patients in phase III data. Periorbital puffiness, particularly on waking, is the most noticeable cosmetic complaint. Keeping sodium intake below 2,300 mg/day and elevating the head of the bed 15 to 30 degrees reduces morning puffiness in most cases. GH-related fluid retention resolves within 2 to 3 weeks of dose reduction if symptomatic edema is present.

Special Populations and Considerations

Women on Hormone Therapy

Estrogen increases IGF-binding protein-3 (IGFBP-3), which lowers free IGF-1. Women taking oral estrogen (combined oral contraceptives or oral HRT) may need a higher tesamorelin dose to achieve equivalent IGF-1 elevation compared with transdermal estrogen users. A pharmacokinetic study in GH-deficient women showed that oral estrogen reduced IGF-1 response to GH by 35 to 45%, while transdermal estrogen had no significant effect. The same dynamic likely applies to tesamorelin. Checking IGF-1 at 6 weeks (rather than 12) in women on oral estrogen allows earlier dose adjustment.

Patients with Pre-Existing Skin Conditions

Psoriasis and atopic dermatitis have not been studied in tesamorelin trials. IGF-1 may exacerbate psoriatic plaques by stimulating keratinocyte proliferation. A case series of 8 patients with psoriasis who received recombinant GH reported plaque worsening in 3 cases within 8 weeks of initiation. Prescribers managing patients with active psoriasis should coordinate with dermatology before starting tesamorelin and schedule a skin review at 6 weeks.

Older Adults

Adults over 65 have lower baseline IGF-1 and larger relative increments with GHRH stimulation. The collagen benefit may be more pronounced, but so is the risk of carpal tunnel syndrome and peripheral edema. An analysis of GH safety in older adults recommended maintaining IGF-1 in the lower half of the age-adjusted reference range in patients over 65 to minimize soft-tissue side effects, a principle directly applicable to tesamorelin dosing in this group.

Stopping Tesamorelin: Skin and Hair Reversal Timeline

Tesamorelin's effects on hair and skin are not permanent. Within 2 to 4 weeks of stopping the drug, IGF-1 returns to pre-treatment baseline. Collagen synthesis rates fall accordingly. Patients who discontinue after 26 weeks of treatment can expect:

• Skin firmness improvements to gradually reverse over 2 to 4 months
• Increased hair growth rate to normalize within 4 to 8 weeks
• Injection-site erythema and sebaceous excess to resolve within 2 to 3 weeks
• Acne flares triggered by tesamorelin to improve within 4 to 6 weeks of stopping

The 26-week withdrawal arm of the Falutz extension study documented that VAT returned to near-baseline within 6 months of stopping, consistent with loss of IGF-1 signaling across all target tissues, skin and fat alike.